Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | KMT2A G3899V |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04659616 | Phase I | Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04307576 | Phase III | Imatinib Blinatumomab Inotuzumab ozogamicin | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Recruiting | DEU | BEL | 11 |
NCT02419755 | Phase II | Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | Terminated | USA | 0 |
NCT05326516 | Phase I | SNDX-5613 | A Study of SNDX-5613 in Combination With Chemotherapy in Participants With Leukemia | Recruiting | USA | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03613532 | Phase I | Busulfan + Fludarabine + Venetoclax | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN | Recruiting | USA | 0 |
NCT03826992 | Phase I | CPX-351 + Venetoclax | Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | Suspended | USA | 0 |
NCT03513484 | Phase I | Azacitidine + Nintedanib | Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04326439 | Phase II | Cytarabine + Etoposide Cytarabine + Etoposide + Sorafenib Asparaginase Erwinia chrysanthemi + Cytarabine + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Sorafenib Cytarabine + Mitoxantrone + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Mitoxantrone | AflacLL1901 (CHOA-AML) | Terminated | USA | 0 |
NCT03114865 | Phase Ib/II | Blinatumomab + Dexamethasone | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | Recruiting | USA | 0 |
NCT04752163 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + DS-1594b + Filgrastim + Mesna + Methotrexate + Vincristine Sulfate DS-1594b + Prednisone + Vincristine Sulfate DS-1594b Azacitidine + DS-1594b + Venetoclax Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate + Rituximab | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03724084 | Phase Ib/II | Cytarabine + Daunorubicin + Pinometostat | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | Active, not recruiting | USA | 0 |
NCT02828358 | Phase II | Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | Active, not recruiting | USA | CAN | 2 |
NCT02141828 | Phase I | Pinometostat | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | Completed | USA | CAN | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT04065399 | Phase Ib/II | SNDX-5613 | A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) | Recruiting | USA | CAN | 2 |
NCT01338987 | Phase II | Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | Completed | USA | 0 |
NCT04811560 | Phase I | JNJ-75276617 | A Study of JNJ-75276617 in Participants With Acute Leukemia | Recruiting | USA | FRA | ESP | 2 |
NCT05453903 | Phase I | JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 | A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | Recruiting | USA | ITA | FRA | ESP | DEU | 2 |
NCT02487459 | Phase I | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma | Recruiting | USA | 0 |